Hansa Biopharma — Marts 2022
-
Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix[
] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients -
Hansa Biopharma completes the AMNOG reimbursement process for Idefirix
in Germany
Hansa and National Association of Statutory Health Insurance Funds (GKV-SV) agree on reimbursement price
German hospitals can receive extra funding for the final reimbursement price based on a positive NUB status 1 decision -
Hansa Biopharma: Expanding launch foundation
"The German reimbursement agreement and expanding hospital financing support is distinctly positive. Over the next 12-24 months, we can expect a gradual expansion for the use of Idefirix across European leading centers, and this is an essential step in the right direction."
-
IR-chef øger aktiebesiddelsen i Hansa Bioharma
Den 16. marts har Klaus Sindahl købt 3.000 aktier i biotekselskabet Hansa Bioharma, hvor han er chef for IR. Aktierne blev købt for kursen 58kr pr. aktie, en aftale på 174.000kr. Aftalen blev indgået i Nasdaq Stockholm. Det fremgår af Finanstilsynets indsigtsregister. -
Med hensyn til Systematica, så det nok ikke helt korrekt at de har "stengt" hele deres shortposition, de har nok nærmere nedbragt den fra 0,59 % til lige under de 0,5 %, så de ikke har oplysningspligt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind